TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01814839

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT01126294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Description: Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
Study: NCT01091740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZES resolute (Endeavor Resolute)
Description: 2nd generation drug eluting stent, which is coated with zotarolimus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EES (Xience)
Description: 2nd generation drug eluting stent, which is coated with everolimus
Study: NCT02097381

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir
Description: Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day).
Study: NCT03311516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New functional insulin therapy
Description: the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
Study: NCT01126294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Description: Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
Study: NCT02603172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
Study: NCT03311516

Intervention type: OTHER
Group type: OTHER
Intervention: functional insulin therapy
Description: the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
Study: NCT00111631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-IV Inhibitor
Description: Escalating doses po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-IV Inhibitor
Description: Escalating doses po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-IV Inhibitor
Description: Escalating doses po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: As prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid
Study: NCT03809936

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real tDCS
Description: Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: For the sham condition(sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
Study: NCT01391832

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnet Stimulation (rTMS)
Description: For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
Study: NCT02503397

Intervention type: DEVICE
Intervention: Auditory brainstem evoked response (ABR)
Description: Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes

Intervention type: DEVICE
Intervention: Auditory brainstem evoked response (ABR)
Description: Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
Study: NCT04559126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-297
Description: EDP-297 Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-297
Description: EDP-297 Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP-297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP-297
Study: NCT01939899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Description: Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
Study: NCT05674669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide (LSD) 50µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide (LSD) 75µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide (LSD) 100µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/Lysergic Acid Diethylamide (LSD) 75µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide (LSD) 50µg/75µg
Study: NCT02603172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3039294
Description: GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
Study: NCT03631433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: identical appearing tablets containing 600 mg of ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen 600 mg and acetaminophen 650 mg
Description: identical appearing tablets of the combination of ibuprofen and acetaminophen
Study: NCT03847259

Intervention type: DIAGNOSTIC_TEST
Intervention: mechanical posture changes
Description: evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).

Intervention type: DIAGNOSTIC_TEST
Intervention: mechanical posture changes
Description: evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
Study: NCT00351299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion titrated to effect

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care per treating physician preference
Study: NCT02436174

Intervention type: DEVICE
Intervention: novel device
Description: novel device being used to measure shivering
Study: NCT04422236

Intervention type: DEVICE
Intervention: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Description: Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creation of anastomoses during laparoscopic bariatric surgery, manufactured by Ezisurg Medical.
Study: NCT02948504

Intervention type: PROCEDURE
Intervention: Coiling or Clipping
Description: All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
Study: NCT05505149

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
Study: NCT02112461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCP-Hospice Alert
Description: The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
Study: NCT00070200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01941082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6867461
Description: Single or multiple ascending dose by intravitreal injection
Study: NCT04238858

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
Study: NCT02673528

Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy

Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy

Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
Study: NCT03669107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gum
Description: no gum
Study: NCT01995786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goal Directed Fluid Therapy FloTrac/Vigileo
Study: NCT02552823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group2
Study: NCT02339376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Study: NCT01886352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Injection of Levobupivacaine in portal sites.
Description: All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Injection of Levobupivacaine in portal sites.
Description: All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Injection of Levobupivacaine in portal sites.
Description: All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
Study: NCT02640092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GTP1
Description: Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.
Study: NCT03454178

Intervention type: DIAGNOSTIC_TEST
Intervention: WatchBP Office (BP measurement machine)
Description: BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
Study: NCT03956121

Intervention type: OTHER
Intervention: injection of magnesium sulfate
Description: The intervention consists to perform a study of the usual fetal heart rate with, in addition, comparison analysis of the short-term variability before and after injection of magnesium sulfate in the exposed group. Two successive short-term variability analyzes will be performed in fetuses of the control group.
Study: NCT03899441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
Study: NCT02387515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive rehabilitation program
Description: Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
Study: NCT00569530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infasurf (ONY Inc.)
Description: Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
Study: NCT02507544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-818 capsules
Study: NCT01226771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin loading dose given
Description: PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Priming dose of ribavirin given
Description: Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C (Standard-of-Care)
Description: PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks